Recommendations for the prevention and treatment of adverse effects of intravesical BCG

Actas urologicas espanolas Pub Date : 2026-10-01 Epub Date: 2026-07-07 DOI:10.1016/j.acuroe.2026.502005

J.L. Alvarez-Ossorio, M. Alvarez-Maestro, J.M. Cozar-Olmo, M. Espinosa-Bosch, I. Florido-Pérez, F. Guerrero-Ramos, L. Martinez-Piñeiro, J. Olivares-Corral, M. Rodriguez-Quecedo, O. Rodriguez-Faba

{"title":"Recommendations for the prevention and treatment of adverse effects of intravesical BCG","authors":"J.L. Alvarez-Ossorio, M. Alvarez-Maestro, J.M. Cozar-Olmo, M. Espinosa-Bosch, I. Florido-Pérez, F. Guerrero-Ramos, L. Martinez-Piñeiro, J. Olivares-Corral, M. Rodriguez-Quecedo, O. Rodriguez-Faba","doi":"10.1016/j.acuroe.2026.502005","DOIUrl":null,"url":null,"abstract":"<div><div>Intravesical Calmette-Guérin bacillus (BCG) instillation is the treatment of choice after transurethral resection of intermediate- and high-risk non-muscle-invasive bladder tumors (NMIBT). However, adverse effects (AEs) of BCG are common and can compromise adherence to treatment. Therefore, a group of experts in urology, hospital pharmacy and nursing reviewed the most recent literature and developed a series of practical recommendations for the prevention, early detection, and treatment of adverse events (AEs) associated with BCG vaccination. These include a questionnaire for AE detection, the treatment of the most common local and systemic AEs, and precautionary recommendations, ranging from BCG preparation to excreta management. Special attention has been given to a multidisciplinary and coordinated approach between urologists, hospital pharmacists and nurses to optimize treatment adherence.</div></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"50 8","pages":"Article 502005"},"PeriodicalIF":0.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173578626001502","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/7 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Intravesical Calmette-Guérin bacillus (BCG) instillation is the treatment of choice after transurethral resection of intermediate- and high-risk non-muscle-invasive bladder tumors (NMIBT). However, adverse effects (AEs) of BCG are common and can compromise adherence to treatment. Therefore, a group of experts in urology, hospital pharmacy and nursing reviewed the most recent literature and developed a series of practical recommendations for the prevention, early detection, and treatment of adverse events (AEs) associated with BCG vaccination. These include a questionnaire for AE detection, the treatment of the most common local and systemic AEs, and precautionary recommendations, ranging from BCG preparation to excreta management. Special attention has been given to a multidisciplinary and coordinated approach between urologists, hospital pharmacists and nurses to optimize treatment adherence.

查看原文本刊更多论文

预防和治疗膀胱内卡介苗不良反应的建议。

膀胱内卡介苗（卡介苗）是经尿道中、高危非肌肉侵袭性膀胱肿瘤（NMIBT）切除术后的首选治疗方法。然而，卡介苗的不良反应（ae）是常见的，并可能影响治疗的依从性。因此，泌尿外科、医院药学和护理学的一组专家回顾了最近的文献，并制定了一系列关于预防、早期发现和治疗卡介苗接种相关不良事件（ae）的实用建议。这些包括AE检测问卷，最常见的局部和全身AE的治疗，以及从卡介苗制备到排泄物管理的预防建议。特别关注泌尿科医生、医院药剂师和护士之间的多学科和协调方法，以优化治疗依从性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas

自引率

0.00%

发文量